Bumetanide

CHEMBL1072 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
364.4 g/mol
LogP
2.8
Phase
4

A potent loop diuretic used to remove excess fluid in conditions such as heart failure, liver cirrhosis, and kidney disease. It works in the loop of Henle in the kidney to block sodium and chloride reabsorption, significantly increasing urine output. It is substantially more potent than furosemide on a milligram basis.

Peso molecular

364,4000 g/mol

LogP

2,80

TPSA

127,00 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Mecanismo de acción

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1

InChI

InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)

Molecular Formula

C17H20N2O5S

HBD / HBA

3 / 7

Enlaces Rotables

8

Átomos Pesados

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A potent loop diuretic used to remove excess fluid in conditions such as heart failure, liver cirrhosis, and kidney disease. It works in the loop of Henle in the kidney to block sodium and chloride reabsorption, significantly increasing urine output. It is substantially more potent than furosemide on a milligram basis.

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Yes, Bumetanide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1072. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2471. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.